IBAB logo

Ion Beam Applications Stock Price

Symbol: ENXTBR:IBABMarket Cap: €333.6mCategory: Healthcare

IBAB Share Price Performance

€11.40
-0.64 (-5.32%)
31.6% undervalued intrinsic discount
€16.67
Fair Value
€11.40
-0.64 (-5.32%)
31.6% undervalued intrinsic discount
€16.67
Fair Value
Price €11.40
AnalystConsensusTarget €16.67

IBAB Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value €16.67 31.6% undervalued intrinsic discount

Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative

Recent IBAB News & Updates

No updates

Ion Beam Applications SA Key Details

€498.2m

Revenue

€332.2m

Cost of Revenue

€166.0m

Gross Profit

€156.7m

Other Expenses

€9.3m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 28, 2025
Earnings per share (EPS)
0.32
Gross Margin
33.32%
Net Profit Margin
1.86%
Debt/Equity Ratio
13.5%

Ion Beam Applications SA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About IBAB

Founded
1986
Employees
2203
CEO
Olivier Legrain
WebsiteView website
www.iba-worldwide.com

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. It also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Belgian Market Performance

  • 7 Days: 1.3%
  • 3 Months: 3.7%
  • 1 Year: 7.6%
  • Year to Date: 8.1%
The market has climbed 1.3% in the last 7 days, lead by the Financials sector with a gain of 3.7%. As for the past 12 months, the market is up 7.6%. Earnings are forecast to grow by 14% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading